Target Name: CDC37L1
NCBI ID: G55664
Review Report on CDC37L1 Target / Biomarker Content of Review Report on CDC37L1 Target / Biomarker
CDC37L1
Other Name(s): cell division cycle 37 like 1, HSP90 cochaperone | cell division cycle 37 homolog-like 1 | HARC | Cell division cycle 37 like 1, HSP90 cochaperone | Hsp90-associating relative of Cdc37 | Hsp90 co-chaperone Cdc37-like 1 | CDC37 cell division cycle 37 homolog-like 1 | CD37L_HUMAN | cell division cycle 37 like 1 | FLJ20639 | CDC37B | RP11-6J24.5

CD37L1: A Promising Drug Target and Biomarker for Cell Division Cycle 37 Like 1

Cell division cycle (CDC) is a critical process that regulates cell growth, proliferation, and differentiation. The CDC is composed of three phases: G1, S, and G2. Cell division cycle 37 like 1 (CDC37L1) is a protein that plays a significant role in the G1 phase of the CDC. It is a cochaperone that helps to transport and regulate the movement of chromosomes during the S phase. CD37L1 is also known as HSP90 cochaperone, which is a protein that contains a unique nucleotide-binding oligomerization domain (NBO domain) and a hydrophobic transmembrane region (TMD).

The HSP90 protein is a heat-activated protein that can exist in two interconvertible forms: a monomeric form and a dimeric form. The monomeric form is predominantly localized to the cytoplasm, while the dimeric form is primarily localized to the nucleus. CD37L1 is a 14-kDa protein that is predominantly localized to the nucleus, and it interacts with the HSP90 dimeric form.

CD37L1 functions as a cochaperone for the HSP90 dimeric form during the S phase of the CDC. It helps to regulate the movement of chromatin during the S phase by interacting with the NBO domain of HSP90. The NBO domain is a unique protein domain that contains a specific sequence of amino acids that is known to play a critical role in the association of nucleotides with the protein. The NBO domain is responsible for the protein's stability, localization, and interaction with other proteins.

CD37L1 has been identified as a potential drug target due to its unique functions in the CDC. One of the main reasons for its potential as a drug target is its involvement in the regulation of cell proliferation. CD37L1 has been shown to play a role in the regulation of cell cycle progression by interacting with the growth factors, such as Wnt, TGF-β, and NF-kappa-B.

Another reason for its potential as a drug target is its involvement in the regulation of cell survival. CD37L1 has been shown to play a role in the regulation of cell survival by interacting with the anti-apoptotic protein, Bcl-2.

CD37L1 has also been shown to play a role in the regulation of cell adhesion. CD37L1 has been shown to interact with the adhesion molecule, E-cadherin.

CD37L1 is a 14-kDa protein that is predominantly localized to the nucleus during the S phase of the CDC. It functions as a cochaperone for the HSP90 dimeric form during the S phase. CD37L1 has been shown to play a role in the regulation of cell cycle progression, cell survival, and cell adhesion. As a result, CD37L1 is a promising drug target and biomarker for cell division cycle 37 like 1.

Conclusion

CD37L1 is a 14-kDa protein that is predominantly localized to the nucleus during the S phase of the CDC. It functions as a cochaperone for the HSP90 dimeric form during the S phase of the CDC. CD37L1 has been shown to play a role in the regulation of cell cycle progression, cell survival, and cell adhesion. As a result, CD37L1 is a promising drug target and biomarker for cell division cycle 37 like 1. Further studies are needed to fully understand its functions in the CDC and its potential as a drug.

Protein Name: Cell Division Cycle 37 Like 1, HSP90 Cochaperone

Functions: Co-chaperone that binds to numerous proteins and promotes their interaction with Hsp70 and Hsp90

The "CDC37L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC37L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5